Tandem Diabetes Care, a global leader in insulin delivery and diabetes technology, announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the Android version of the Tandem Mobi mobile app.
Tandem Mobi is the world’s smallest, durable automated insulin delivery system, powered by Control-IQ+ technology. Reported Control-IQ+ benefits include:
Day 1 improvements
79% time in range
90% overnight time in range
“We’re excited to bring Tandem Mobi and the best-in-class outcomes of Control-IQ+ to Android users,” said John Sheridan, president and chief executive officer. “This latest integration gives Android users access to the life-changing benefits of Control-IQ+ on a system that emphasizes convenience, discretion, and customization.”
The newly cleared Android app enables secure, seamless pairing with the Tandem Mobi insulin pump, allowing users to manage their diabetes directly from a compatible smartphone. Integration with the Tandem Source platform supports improved communication between patients and healthcare providers, helping guide more informed treatment decisions.
“With the Tandem Mobi mobile app, we’re delivering a solution that meets patients where they are, on the devices they use every day, while maintaining the safety, reliability, and innovation they expect from Tandem,” said Dr. Jordan Pinsker, chief medical officer.
A limited release is planned for December 2025, followed by full commercial availability in early 2026. Once launched, the Tandem Mobi Android app will be available on the Google Play Store for supported smartphones, including Google Pixel 6–10 and Samsung Galaxy S21–S25. A comprehensive compatibility list will be published closer to launch.
Also Read